<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26962150</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>10</Issue><PubDate><Year>2016</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy.</ArticleTitle><Pagination><StartPage>1979</StartPage><EndPage>1989</EndPage><MedlinePgn>1979-1989</MedlinePgn></Pagination><Abstract><AbstractText>Spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease) is one of nine neurodegenerative disorders that are caused by expansion of polyglutamine-encoding CAG repeats. Intracellular accumulation of abnormal proteins in these diseases, a pathological hallmark, is associated with defects in protein homeostasis. Enhancement of the cellular proteostasis capacity with small molecules has therefore emerged as a promising approach to treatment. Here, we characterize a novel curcumin analog, ASC-JM17, as an activator of central pathways controlling protein folding, degradation and oxidative stress resistance. ASC-JM17 acts on Nrf1, Nrf2 and Hsf1 to increase the expression of proteasome subunits, antioxidant enzymes and molecular chaperones. We show that ASC-JM17 ameliorates toxicity of the mutant androgen receptor (AR) responsible for SBMA in cell, fly and mouse models. Knockdown of the Drosophila Nrf1 and Nrf2 ortholog cap 'n' collar isoform-C, but not Hsf1, blocks the protective effect of ASC-JM17 on mutant AR-induced eye degeneration in flies. Our observations indicate that activation of the Nrf1/Nrf2 pathway is a viable option for pharmacological intervention in SBMA and potentially other polyglutamine diseases.</AbstractText><CopyrightInformation>Published by Oxford University Press 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bott</LastName><ForeName>Laura C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892, USA, Department of Cell and Molecular Biology, Karolinska Institutet, 17177 Stockholm, Sweden, laura.bott@northwestern.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badders</LastName><ForeName>Nisha M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ke-Lian</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harmison</LastName><ForeName>George G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bautista</LastName><ForeName>Elaine</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Charles C-Y</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>AndroScience Corporation, Solana Beach, CA 92075, USA and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobue</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>J Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dantuma</LastName><ForeName>Nico P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Karolinska Institutet, 17177 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischbeck</LastName><ForeName>Kenneth H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA NS003038-10</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS069515</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS053825</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C410798">AR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000621364">ASC-JM17</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076249">Heat Shock Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C053134">Hsf protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051265">NF-E2-Related Factor 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>26700-71-0</RegistryNumber><NameOfSubstance UI="C097188">polyglutamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>IT942ZTH98</RegistryNumber><NameOfSubstance UI="D003474">Curcumin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003474" MajorTopicYN="N">Curcumin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076249" MajorTopicYN="N">Heat Shock Transcription Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020966" MajorTopicYN="N">Muscular Disorders, Atrophic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051265" MajorTopicYN="N">NF-E2-Related Factor 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26962150</ArticleId><ArticleId IdType="pmc">PMC5062587</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddw073</ArticleId><ArticleId IdType="pii">ddw073</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Orr H.T., Zoghbi H.Y. (2007) Trinucleotide repeat disorders. Annu. Rev. Neurosci., 30, 575&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">17417937</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada A.R., Wilson E.M., Lubahn D.B., Harding A.E., Fischbeck K.H. (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature, 352, 77&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman A.P., Harmison G., Strand A.D., Olson J.M., Fischbeck K.H. (2002) Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum. Mol. Genet., 11, 1967&#x2013;1976.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165558</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M., Adachi H., Minamiyama M., Waza M., Tokui K., Banno H., Suzuki K., Onoda Y., Tanaka F., Doyu M. et al. (2006) Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration. J. Neurosci., 26, 12106&#x2013;12117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675422</ArticleId><ArticleId IdType="pubmed">17122035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S., Harmison G.G., Meyertholen K., Pennuto M., Burnett B.G., Fischbeck K.H. (2009) Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum. Mol. Genet., 18, 27&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644643</ArticleId><ArticleId IdType="pubmed">18824496</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z., Wang A.M., Robins D.M., Lieberman A.P. (2009) Altered RNA splicing contributes to skeletal muscle pathology in Kennedy disease knock-in mice. Dis. Mod. Mech., 2, 500&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737058</ArticleId><ArticleId IdType="pubmed">19692580</ArticleId></ArticleIdList></Reference><Reference><Citation>Balch W.E., Morimoto R.I., Dillin A., Kelly J.W. (2008) Adapting proteostasis for disease intervention. Science, 319, 916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">18276881</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirkkala L., Nykanen P., Sistonen L. (2001) Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB J., 15, 1118&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">11344080</ArticleId></ArticleIdList></Reference><Reference><Citation>Adachi H., Katsuno M., Minamiyama M., Sang C., Pagoulatos G., Angelidis C., Kusakabe M., Yoshiki A., Kobayashi Y., Doyu M. et al. (2003) Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J. Neurosci., 23, 2203&#x2013;2211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742038</ArticleId><ArticleId IdType="pubmed">12657679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey C.K., Andriola I.F., Kampinga H.H., Merry D.E. (2002) Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum. Mol. Genet., 11, 515&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">11875046</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi Y., Kume A., Li M., Doyu M., Hata M., Ohtsuka K., Sobue G. (2000) Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem., 275, 8772&#x2013;8778.</Citation><ArticleIdList><ArticleId IdType="pubmed">10722721</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyttenbach A., Sauvageot O., Carmichael J., Diaz-Latoud C., Arrigo A.P., Rubinsztein D.C. (2002) Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet., 11, 1137&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">11978772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kensler T.W., Wakabayashi N., Biswal S. (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol., 47, 89&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">16968214</ArticleId></ArticleIdList></Reference><Reference><Citation>Radhakrishnan S.K., Lee C.S., Young P., Beskow A., Chan J.Y., Deshaies R.J. (2010) Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol. Cell, 38, 17&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2874685</ArticleId><ArticleId IdType="pubmed">20385086</ArticleId></ArticleIdList></Reference><Reference><Citation>Sha Z., Goldberg A.L. (2014) Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97. Curr. Biol., 24, 1573&#x2013;1583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4108618</ArticleId><ArticleId IdType="pubmed">24998528</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershko A., Ciechanover A. (1998) The ubiquitin system. Annu. Rev. Biochem., 67, 425&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">9759494</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatraman P., Wetzel R., Tanaka M., Nukina N., Goldberg A.L. (2004) Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol. Cell, 14, 95&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">15068806</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt G., Rechsteiner M. (2008) Proteasomes cleave at multiple sites within polyglutamine tracts: activation by PA28gamma(K188E). J. Biol. Chem., 283, 12919&#x2013;12925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442343</ArticleId><ArticleId IdType="pubmed">18343811</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I., Stack C., Kong L., Musaro A., Adachi H., Katsuno M., Sobue G., Taylor J.P., Sumner C.J., Fischbeck K.H. et al. (2009) Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron, 63, 316&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735765</ArticleId><ArticleId IdType="pubmed">19679072</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokui K., Adachi H., Waza M., Katsuno M., Minamiyama M., Doi H., Tanaka K., Hamazaki J., Murata S., Tanaka F. et al. (2009) 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum. Mol. Genet., 18, 898&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">19066230</ArticleId></ArticleIdList></Reference><Reference><Citation>Waza M., Adachi H., Katsuno M., Minamiyama M., Sang C., Tanaka F., Inukai A., Doyu M., Sobue G. (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med., 11, 1088&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155577</ArticleId></ArticleIdList></Reference><Reference><Citation>Alavez S., Vantipalli M.C., Zucker D.J., Klang I.M., Lithgow G.J. (2011) Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. Nature, 472, 226&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610427</ArticleId><ArticleId IdType="pubmed">21451522</ArticleId></ArticleIdList></Reference><Reference><Citation>Calamini B., Silva M.C., Madoux F., Hutt D.M., Khanna S., Chalfant M.A., Saldanha S.A., Hodder P., Tait B.D., Garza D. et al. (2012) Small-molecule proteostasis regulators for protein conformational diseases. Nat. Chem. Biol., 8, 185&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262058</ArticleId><ArticleId IdType="pubmed">22198733</ArticleId></ArticleIdList></Reference><Reference><Citation>Brondino N., Re S., Boldrini A., Cuccomarino A., Lanati N., Barale F., Politi P. (2014) Curcumin as a therapeutic agent in dementia: a mini systematic review of human studies. Sci. World J., 2014, 174282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3919104</ArticleId><ArticleId IdType="pubmed">24578620</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtsu H., Xiao Z., Ishida J., Nagai M., Wang H.K., Itokawa H., Su C.Y., Shih C., Chiang T., Lee Y. et al. (2002) Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J. Med. Chem., 45, 5037&#x2013;5042.</Citation><ArticleIdList><ArticleId IdType="pubmed">12408714</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M., Adachi H., Kume A., Li M., Nakagomi Y., Niwa H., Sang C., Kobayashi Y., Doyu M., Sobue G. (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron, 35, 843&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedelsky N.B., Pennuto M., Smith R.B., Palazzolo I., Moore J., Nie Z., Neale G., Taylor J.P. (2010) Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron, 67, 936&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514079</ArticleId><ArticleId IdType="pubmed">20869592</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z., Chang Y.J., Yu I.C., Yeh S., Wu C.C., Miyamoto H., Merry D.E., Sobue G., Chen L.M., Chang S.S. et al. (2007) ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat. Med., 13, 348&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">17334372</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunseich C., Kats I.R., Bott L.C., Rinaldi C., Kokkinis A., Fox D., Chen K.L., Schindler A.B., Mankodi A.K., Shrader J.A. et al. (2014) Early onset and novel features in a spinal and bulbar muscular atrophy patient with a 68 CAG repeat. Neuromuscul. Disord., 24, 978&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252652</ArticleId><ArticleId IdType="pubmed">25047668</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Crouch D.H., Yamamoto M., Hayes J.D. (2006) Negative regulation of the Nrf1 transcription factor by its N-terminal domain is independent of Keap1: Nrf1, but not Nrf2, is targeted to the endoplasmic reticulum. Biochem. J., 399, 373&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1615900</ArticleId><ArticleId IdType="pubmed">16872277</ArticleId></ArticleIdList></Reference><Reference><Citation>Radhakrishnan S.K., den Besten W., Deshaies R.J. (2014) p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition. eLife, 3, e01856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896944</ArticleId><ArticleId IdType="pubmed">24448410</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimberg K.B., Beskow A., Lundin D., Davis M.M., Young P. (2011) Basic leucine zipper protein Cnc-C is a substrate and transcriptional regulator of the Drosophila 26S proteasome. Mol. Cell. Biol., 31, 897&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3028647</ArticleId><ArticleId IdType="pubmed">21149573</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt W.B., Gestwicki J.E., Osawa Y., Lieberman A.P. (2015) Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol., 55, 353&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4372135</ArticleId><ArticleId IdType="pubmed">25292434</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A.M., Miyata Y., Klinedinst S., Peng H.M., Chua J.P., Komiyama T., Li X., Morishima Y., Merry D.E., Pratt W.B. et al. (2013) Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat. Chem. Biol., 9, 112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552084</ArticleId><ArticleId IdType="pubmed">23222885</ArticleId></ArticleIdList></Reference><Reference><Citation>Sittler A., Lurz R., Lueder G., Priller J., Lehrach H., Hayer-Hartl M.K., Hartl F.U., Wanker E.E. (2001) Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet., 10, 1307&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">11406612</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M., Sang C., Adachi H., Minamiyama M., Waza M., Tanaka F., Doyu M., Sobue G. (2005) Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc. Natl. Acad. Sci. USA, 102, 16801&#x2013;16806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1275598</ArticleId><ArticleId IdType="pubmed">16260738</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik B., Nirmalananthan N., Gray A.L., La Spada A.R., Hanna M.G., Greensmith L. (2013) Co-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapy. Brain, 136, 926&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624668</ArticleId><ArticleId IdType="pubmed">23393146</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo N., Katsuno M., Adachi H., Minamiyama M., Doi H., Matsumoto S., Miyazaki Y., Iida M., Tohnai G., Nakatsuji H. et al. (2013) Heat shock factor-1 influences pathological lesion distribution of polyglutamine-induced neurodegeneration. Nat. Comm., 4, 1405.</Citation><ArticleIdList><ArticleId IdType="pubmed">23360996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bersuker K., Hipp M.S., Calamini B., Morimoto R.I., Kopito R.R. (2013) Heat shock response activation exacerbates inclusion body formation in a cellular model of Huntington disease. J. Biol. Chem., 288, 23633&#x2013;23638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3745309</ArticleId><ArticleId IdType="pubmed">23839939</ArticleId></ArticleIdList></Reference><Reference><Citation>Barone M.C., Sykiotis G.P., Bohmann D. (2011) Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a Drosophila model of Parkinson's disease. Dis. Mod. Mech., 4, 701&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3180234</ArticleId><ArticleId IdType="pubmed">21719443</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.Y., Kwong M., Lu R., Chang J., Wang B., Yen T.S., Kan Y.M. (1998) Targeted disruption of the ubiquitous CNC-bZIP transcription factor, Nrf-1, results in anemia and embryonic lethality in mice. EMBO J., 17, 1779&#x2013;1787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1170525</ArticleId><ArticleId IdType="pubmed">9501099</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmer S.C., Sun C.W., Winnier G.E., Hogan B.L., Townes T.M. (1997) The bZIP transcription factor LCR-F1 is essential for mesoderm formation in mouse development. Genes Dev., 11, 786&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">9087432</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K., Lu R., Chang J.C., Kan Y.W. (1996) NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc. Natl. Acad. Sci. USA, 93, 13943&#x2013;13948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19474</ArticleId><ArticleId IdType="pubmed">8943040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubbs A.F., Benkovic S.A., Miller D.B., O'Callaghan J.P., Battelli L., Schwegler-Berry D., Ma Q. (2007) Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2. Am. J. Pathol., 170, 2068&#x2013;2076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1899457</ArticleId><ArticleId IdType="pubmed">17525273</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilchez D., Morantte I., Liu Z., Douglas P.M., Merkwirth C., Rodrigues A.P., Manning G., Dillin A. (2012) RPN-6 determines C. elegans longevity under proteotoxic stress conditions. Nature, 489, 263&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">22922647</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee B.H., Lee M.J., Park S., Oh D.C., Elsasser S., Chen P.C., Gartner C., Dimova N., Hanna J., Gygi S.P. et al. (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature, 467, 179&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2939003</ArticleId><ArticleId IdType="pubmed">20829789</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas M.R., Johnson D.A., Sirkis D.W., Messing A., Johnson J.A. (2008) Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J. Neurosci., 28, 13574&#x2013;13581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866507</ArticleId><ArticleId IdType="pubmed">19074031</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y.N., Yu Y.V., Gundemir S., Jo C., Cui M., Tieu K., Johnson G.V. (2013) Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin. PLoS ONE, 8, e57932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3585875</ArticleId><ArticleId IdType="pubmed">23469253</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Hettinger C.L., Zhang D., Rezvani K., Wang X., Wang H. (2014) Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington's disease. J. Neurochem., 129, 539&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3997618</ArticleId><ArticleId IdType="pubmed">24383989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellrichmann G., Petrasch-Parwez E., Lee D.H., Reick C., Arning L., Saft C., Gold R., Linker R.A. (2011) Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS ONE, 6, e16172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3031519</ArticleId><ArticleId IdType="pubmed">21297955</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi C., Bott L.C., Chen K.L., Harmison G.G., Katsuno M., Sobue G., Pennuto M., Fischbeck K.H. (2012) Insulin like growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy. Mol. Med., 18, 1261&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3521783</ArticleId><ArticleId IdType="pubmed">22952056</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>